Jagsonpal Pharmaceuticals Ltd Fundamentals
Jagsonpal Pharmaceuticals Ltd Financials
Resistance and Support
₹362.85
PIVOT
 Resistance | |
|---|---|
| First Resistance | ₹373.700 |
| Second Resistance | ₹386.350 |
| Third Resistance | ₹397.200 |
 Support | |
|---|---|
| First Support | ₹350.200 |
| Second Support | ₹339.350 |
| Third Support | ₹326.700 |
Delivery and Volume
About Jagsonpal Pharmaceuticals Ltd
Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity. The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the product market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.
Managing Director
1978
Founded
Manish Gupta
NSE Symbol
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd Management
| Name | Designation |
|---|---|
| J S Kochhar | Chairman |
| Manish Gupta | Managing Director |
| A C Chakrabortti | Director |
| Harsha Raghavan | Chairman & Non Executive Dir. |
| Debasis Bikash Nandy | Independent Director |
| S Mukhopadhyay | Director |
| Radhika Dudhat | Independent Director |
| S K Goyal | Director |
| R P S Kochhar | Managing Director |
| Pallavi Dinodia | Independent Director |
| Prithipal Singh Kochhar | Non Executive Director |
| Abhishek Joshi | Company Sec. & Compli. Officer |
| Raj Kumar Kapoor | Company Secretary |
Events
Dividend Announcement for Jagsonpal Pharmaceuticals Ltd - May 23, 2023
On May 23, 2023, shareholders are set to receive a dividend payout, with each share entitling its holder to a dividend of 100.0%. This dividend percentage refle...
Read MoreJagsonpal Pharmaceuticals Ltd News
Similar Stocks
| Company | Market Cap | Market Price | P/E Ratio |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | ₹ 367554.12 Cr | ₹ 1,531.90 (0.03 %) | 89.16 |
| Cipla Ltd | ₹ 113362.29 Cr | ₹ 1,404.05 (0.36 %) | 30.52 |
| Zydus Lifesciences Ltd | ₹ 111083.2 Cr | ₹ 1,103.95 (5.00 %) | 41.35 |
| Divis Laboratories Ltd | ₹ 104302.61 Cr | ₹ 3,929.00 (0.47 %) | 76.42 |
| Dr Reddys Laboratories Ltd | ₹ 96948.1 Cr | ₹ 5,811.60 (0.21 %) | 22.34 |